Another alternative to this is that the 5-HT4 agonist currently available for use in humans do not have great enough potency or bioavailability in the brain to elicit the same effects.
An alternative approach is that existing 5-HT4 agonists used in humans are not potent enough or readily absorbed into the brain, making it difficult to achieve the desired outcomes.